COLL
- Collegium Pharmaceutical, Inc.
()
Overview
Company Summary
Collegium Pharmaceutical, Inc. is a pharmaceutical company that specializes in developing and commercializing innovative medicines meant to address unmet medical needs. The company focuses on developing products for patients suffering from pain and related conditions.
Collegium Pharmaceutical primarily specializes in extended-release formulations, which allow for the controlled release of active ingredients over an extended period. This helps to provide consistent pain relief for patients and reduces the need for frequent dosing.
The company's flagship product is Xtampza ER, an extended-release formulation of oxycodone that is designed to manage chronic pain. Xtampza ER is formulated to deter misuse and abuse, making it a valuable option for patients requiring long-term pain management.
In addition to Xtampza ER, Collegium Pharmaceutical has a pipeline of potential future products. These include formulations for opioids and non-opioid medications that aim to address additional pain conditions and improve patient outcomes.
To summarize, Collegium Pharmaceutical is focused on developing and commercializing extended-release formulations of pain medications, with an emphasis on providing effective pain management options while addressing the need for abuse-deterrence in an effort to improve patient safety.